Timsans Janis, Kauppi Jenni, Rantalaiho Vappu, Kerola Anne, Hakkarainen Kia, Paldanius Mika, Kautiainen Hannu, Kauppi Markku
Department of Rheumatology, Päijät-Häme Central Hospital, Wellbeing Services County of Päijät-Häme, 15850 Lahti, Finland.
Faculty of Medicine and Health Technology, Tampere University, 33100 Tampere, Finland.
Metabolites. 2025 May 28;15(6):356. doi: 10.3390/metabo15060356.
: Hyperuricemia and steatotic liver disease are both associated with various comorbidities and mortality. This study was carried out to study the association between hyperuricemia and steatotic liver disease and to assess the impact of the etiology of hyperuricemia on the development of steatotic liver disease. : Data from a population-based study of 2635 individuals aged 52-76 years was used. Hyperuricemia was defined as a serum urate (SU) of >410 μmol/L (≈6.9 mg/dL; 75th percentile) and steatotic liver disease as a fatty liver index (FLI) of ≥80 (75th percentile). We defined hyperuricemia as renal if estimated glomerular filtration rate (eGFR) was ≤67 mL/min/1.73 m (25th percentile) and as metabolic if eGFR was >67 mL/min/1.73 m. : FLI correlated with SU in women [r = 0.47 (95% CI: 0.43 to 0.51)] and men [r = 0.37 (95% CI: 0.32 to 0.42)]. Compared to those with SU ≤ 410 μmol/L and FLI < 80, the hazard ratio (HR) for all-cause mortality was 1.76 (95% CI: 1.39 to 2.23) in hyperuricemic individuals with FLI ≥ 80, 1.16 (95% CI: 0.95 to 1.40) in hyperuricemic individuals with FLI < 80, and 1.34 (95% CI: 1.06 to 1.70) in persons with SU ≤ 410 μmol/L and FLI ≥ 80. Individuals with metabolic hyperuricemia had a statistically significantly higher FLI than individuals with renal hyperuricemia: mean (SD) = 73.4 (12.2) and 69.6 (22.5), respectively, = 0.015 after adjusting for sex and diabetes. : FLI correlates positively with SU, and it is higher in persons with metabolic hyperuricemia. Both steatotic liver disease and hyperuricemia increase mortality.
高尿酸血症和脂肪性肝病均与多种合并症及死亡率相关。本研究旨在探讨高尿酸血症与脂肪性肝病之间的关联，并评估高尿酸血症的病因对脂肪性肝病发展的影响。：使用了一项基于人群的研究数据，该研究涉及2635名年龄在52 - 76岁的个体。高尿酸血症定义为血清尿酸（SU）>410 μmol/L（≈6.9 mg/dL；第75百分位数），脂肪性肝病定义为脂肪肝指数（FLI）≥80（第75百分位数）。若估计肾小球滤过率（eGFR）≤67 mL/min/1.73 m²（第25百分位数），则将高尿酸血症定义为肾性；若eGFR>67 mL/min/1.73 m²，则定义为代谢性。：FLI在女性[r = 0.47（95%CI：0.43至0.51）]和男性[r = 0.37（95%CI：0.32至0.42）]中均与SU相关。与SU≤410 μmol/L且FLI<80的个体相比，FLI≥80的高尿酸血症个体全因死亡率的风险比（HR）为1.76（95%CI：1.39至2.23），FLI<80的高尿酸血症个体为1.16（95%CI：0.95至1.40），SU≤410 μmol/L且FLI≥80的个体为1.34（95%CI：1.06至1.70）。代谢性高尿酸血症个体的FLI在统计学上显著高于肾性高尿酸血症个体：平均值（标准差）分别为73.4（12.2）和69.6（22.5），在调整性别和糖尿病因素后P = 0.015。：FLI与SU呈正相关，且在代谢性高尿酸血症个体中更高。脂肪性肝病和高尿酸血症均会增加死亡率。
